Mesirow Financial Investment Management Inc. Sells 861 Shares of Becton, Dickinson and Company (NYSE:BDX)

Mesirow Financial Investment Management Inc. trimmed its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,435 shares of the medical instruments supplier’s stock after selling 861 shares during the quarter. Mesirow Financial Investment Management Inc.’s holdings in Becton, Dickinson and Company were worth $3,379,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of BDX. Quantbot Technologies LP grew its position in shares of Becton, Dickinson and Company by 86.6% in the 2nd quarter. Quantbot Technologies LP now owns 30,143 shares of the medical instruments supplier’s stock worth $7,045,000 after buying an additional 13,992 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Becton, Dickinson and Company by 10.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,736,258 shares of the medical instruments supplier’s stock worth $405,726,000 after buying an additional 167,033 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Becton, Dickinson and Company by 1.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 4,905,114 shares of the medical instruments supplier’s stock worth $1,146,374,000 after buying an additional 87,230 shares during the last quarter. Abound Wealth Management grew its position in shares of Becton, Dickinson and Company by 96.0% in the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after buying an additional 96 shares during the last quarter. Finally, Plato Investment Management Ltd grew its position in shares of Becton, Dickinson and Company by 108.5% in the 2nd quarter. Plato Investment Management Ltd now owns 6,141 shares of the medical instruments supplier’s stock worth $1,435,000 after buying an additional 3,196 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Down 0.1 %

Shares of NYSE:BDX opened at $234.04 on Tuesday. The stock has a fifty day simple moving average of $234.88 and a two-hundred day simple moving average of $235.60. The stock has a market capitalization of $67.64 billion, a price-to-earnings ratio of 51.55, a PEG ratio of 1.91 and a beta of 0.42. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $269.52. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The business had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. During the same quarter in the previous year, the business earned $2.96 earnings per share. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. On average, research analysts anticipate that Becton, Dickinson and Company will post 13.1 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be paid a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.62%. The ex-dividend date of this dividend is Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on BDX. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Evercore ISI cut their price objective on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Citigroup dropped their price target on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. The Goldman Sachs Group began coverage on Becton, Dickinson and Company in a research report on Thursday, May 30th. They set a “buy” rating and a $274.00 price target on the stock. Finally, Raymond James dropped their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $279.50.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.